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Abstract
Gene expression profiling is a relatively new technology for the study
of breast cancers, but within the past few years there has been a
rapid rise in interest in its potential to improve the clinical management
of breast cancer. This technology has contributed to our knowledge
of the molecular pathology of breast tumours and shows promise as a
tool to predict response to therapy and outcome, such as risk of
metastasis. Microarray technology is continually developing and it is
becoming apparent that, despite the various platforms available,
robust conclusions can still be drawn that apply across the different
array types. Gene expression profiling is beginning to appear in the
breast cancer clinic but it is not yet fully evaluated. This review
explores the questions that must be addressed before this technology
can become an everyday clinical tool.
Introduction
Ongoing development of a wide spectrum of therapies for
breast cancer has increased the complexity of breast cancer
management in recent years. Clinicians must make decisions
regarding the best treatment for an individual woman, but the
disease parameters currently used to decide upon treatment
are relatively unsophisticated. Furthermore, although these
parameters may predict proportions of the population in
which an outcome may occur fairly accurately, they cannot
identify in which women the outcome will occur. This leads to
over-treatment of many patients and inadequate treatment of
others. High-throughput genomic technologies have been
used to delineate tumour subtypes and response to therapy,
and to identify patient characteristics that may influence
tumour behaviour. One of the keys to improving breast cancer
management is the targeting of treatment to those who will
truly benefit, thereby avoiding iatrogenic morbidity in those
who will not. The use of gene expression profiling is
unfortunately not straightforward, because differences
between the platforms used in studies have led to inconsis-
tencies in results and considerable scepticism. However, as
is discussed below, these problems are not insurmountable
and gene expression profiling shows considerable promise,
but large clinical studies are now needed.
Historical perspective
Clinically measurable characteristics (for instance, tumour
size, spread to lymph nodes, distant metastases and histo-
logical appearance [tumour grade]) and patient
characteristics (such as age and menopausal status) give an
approximate guide to tumour behaviour and formed the basis
of the earliest prognostic indices. Advances in immuno-
histochemistry added oestrogen receptor (ER)-α and
progesterone receptor status, and most recently growth
factor receptor status (epidermal growth factor receptor and
ERBB2 over-expression), Ki-67 and others. Some or all of
these factors are included in indices such as The International
Consensus Guidelines of St Gallen [1] and the Nottingham
Prognostic Index [2], which are widely used to guide
treatment. It has been obvious for years that breast cancer is
a heterogeneous disease, and more recently it has become
apparent that dissection of the molecular basis of
malignancies classifies tumours into increasingly large
numbers of subtypes that require individualized treatment.
The advent of genomics and proteomics could be regarded
as a natural progression from the use of only a few markers to
the combination of large numbers of markers – ‘tumour
signatures’ – that can define tumour subtypes and predict
outcome.
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Gene expression approaches to classification,
prognostication and determining response to
treatments
The primary focus of work using gene expression microarrays
in the breast cancer field has been the molecular sub-
classification of breast cancer put forward by Perou and
Sorlie and their coworkers [3-6] and the prognosis profiles
proposed by the Amsterdam [7,8] and Rotterdam [9] groups
(Table 1). The luminal and basal-like subtypes have been
repeatedly identified and validated by gene expression
analysis as the most distinctive of three or more molecular
subtypes of breast cancer. Tumours that are positive for
ERBB2 are predominantly identified as a distinct subtype of
breast cancer by the ‘intrinsic’ subtype classification [3-6]
and among the ‘molecular apocrine’ tumours [10]. However,
ERBB2-positive tumours are also found within other classes,
which presumably reflects heterogeneous expression of ER
and their distinctive therapeutic and clinical attributes. The
Table 1
Gene expression studies of breast carcinomas aiming to improve clinical management
Number of 
differentially 
expressed 
Gene expression  cDNAs/oligos/
profiles and  Samples  probe sets 
classifiers Tissue/population included (n) Platform (total) Ref.
Overall  PBC (node –ve, age <55 years) 117 oligo Agilent Hu25k 70 (24,479) [7]
outcome/metastasis PBC (node ±ve, age <53 years) 295 oligo Agilent Hu25k 70 (24,479) [8]
PBC (node –ve, any age) 287 Affymetrix U133A 76 (22,283) [9]
PBC (node –ve, ER+ only) 668 qRT-PCR 21 genes [32,33]
PBC (population and validation cohorts) 448 Affymetrix U133 set 64 (44,792) [37]
Tumour classification PBC (+benign tissues) 65 cDNA (Stanford) 476 (8102) [3]
PBC (+benign tissues) 78 cDNA (Stanford) 476 (8102) [4]
PBC (+benign tissues) 122 cDNA (Stanford) 476 (8102) [5]
PBC (node ±ve) 20 Agilent, Applied  [6]
Biosystems, cDNA 
(Stanford)
PBC + metastases 105 Agilent oligo  1300 (>17,000) [11]
(1Av1, 1Av2)
PBC (node ±) 99 cDNA (NCI) 706 (7650) [38]
ER status PBC (2-5 cm, node –ve) 47 cDNA 100 (6728) [39]
PBC (1.5-5 cm, node ±ve, ER/PR +ve or –ve) 49 Affymetrix HuGeneFL 100 (5600) [40]
PRC (stage I-II, node –ve, ER and PR +ve) 26 SAGE 520 (>50,000) [41]
Nodal status PBC (ER ±ve, node ±ve) 49 Affymetrix U95A 100 (12,626) [42]
Apocrine PBC (large operable/advanced inoperable/inflammatory) 49 Affymetrix U133A 520 (22,283) [10]
Wound Response PBC (node ±ve, age <55 years) 295 Oligo Agilent Hu25k 442 (24,479) [16]
Proliferation PBC (node ±ve, age <55 years) 311 Oligo Agilent Hu25k 50 (24,479) [17]
Grade  PBC (node ±ve, ER ±ve) 189 Affymetrix U133A 128 (22,283) [12]
Grade/progression Normal breast, ADH, DCIS, IDC (LCM) 61 cDNA  200 (1940) [43]
(Research Genetics)
Hereditary breast  PBC (sporadic, BRCA1, BRCA2) 22 DNA clones 176 (6512) [18]
cancer Fibroblasts from normal breast (BRCA1, normal controls) 28 cDNA (IMAGE) 47 (5603) [44]
Tamoxifen resistant PBC (responsive and nonresponsive to tamoxifen) 112 cDNA (NKI) 81 (19,200) [21]
ER response MCF-7 cells and luminal breast tumours 65 cDNA (Agilent) 822 (>17,000) [13]
Neoadjuvant PBC  (docetaxel) 24 Affymetrix  U95A 92  (12,626) [20]
chemotherapy  PBC (doxorubicin/cyclophosphamide) 40 Affymetrix U133A 253 (22,283) [19]
response PBC (doxorubicin) 36 Affymetrix U133A  38 (54,678) [14]
plus2.0
PBC (gemcitabine/epirubicin/docetaxel) 100 Custom made oligo 512 (21,329) [45]
PBC (doxorubicin/cyclophosphamide) 16 cDNA (NCI) 137 (7650) [46]
Whilst we have endeavoured to highlight the major studies in this field, we regret any offence to authors of other important work not included in this
table. ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; ER, oestrogen receptor; IDC, invasive ductal carcinoma; LCM, laser
capture microdissection; PBC, primary breast carcinoma; PR, progesterone receptor; qRT-PCR, quantitative reverse transcription polymerase
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molecular subtypes identified are associated with significantly
different clinical outcomes [4,11] and are likely to respond
best to different treatment approaches.
Traditional classifications of tumours may provide clear-cut
treatment options in high and low risk cases, but often
tumours fall into an ‘intermediate’ group; it is in these
borderline cases that improvements are most urgently
required. In these cases the ‘safe’ option is to over-treat,
benefiting a relatively small minority of cases and exposing the
rest to side effects unnecessarily. Conversely, a more
conservative approach may avoid unwarranted treatment and
additionally reduce costs, but some women that would benefit
may go untreated. Studies that examine links between gene
expression and known prognostic factors such as grade [12]
and ER status [13] may be beneficial for this intermediate
group. Tumour grade is an excellent example; grade 3 tumours
are at much higher risk of recurrence than are grade 1
tumours, but 30-60% of tumours are classified as histological
grade 2. Sotiriou and coworkers [12] recently used gene
expression profiling to reclassify grade 2 tumours into two
groups resembling grade 1 and grade 3 tumours with low and
high risk of recurrence, respectively, thereby better
characterizing these tumours conventionally considered to be
‘intermediate risk’.
Expression profiling has uncovered signatures associated
with distinct phenotypes (Table 1), such as profiles exhibited
by hypoxic tumours or inflammatory breast cancers [14]. A
recent study [15] showed that medullary breast cancer is a
subgroup of basal breast cancers. Novel aspects of tumour
behaviour have been identified by the expression of specific
functional sets of genes such as ‘wound response’ genes
[16]. A ‘proliferation signature’ has been shown to identify
particular patient groups who have an extremely poor
outcome in a subpopulation of breast cancer patients [17].
Gene expression studies have been used to distinguish
between sporadic tumours and tumours from women with
BRCA1 and BRCA2 germline mutations [18]. Tumours from
BRCA1 mutation carriers have been found to be frequently of
the basal subtype, whereas BRCA2 tumours fall mainly within
the luminal A category [5]. Observations such as these may
further our understanding of the pathogenesis of tumours in
mutation carriers.
Response to treatment has also been studied using
expression microarrays. A gene expression profile from
pretreatment tumour biopsies has been found to predict
response to combination doxorubicin/cyclophosphamide
treatment [19]. The genes comprising this profile differed
from those in the same group’s previously reported profile for
predicting response to docetaxel therapy [20]. Similarly,
response to tamoxifen can be predicted by expression
profiling [21]. These exciting results suggest that predictive
profiles could potentially be found for any given
chemotherapy or endocrine regimen.
Influences of genetic background on outcome
The finding that tumours from BRCA1 mutation carriers are
predominantly of the basal subtype clearly demonstrates that
genetic background can predispose to a particular tumour
subtype and outcome. Furthermore, a study showed that
oncogene-induced mouse mammary tumors from 31 inbred
strains exhibit differing rates of metastasis [22]. The study
also reported distinct gene expression profiles according to
genetic background. This suggests that the tendency for
metastatic disease to develop may have a germline
component. The existence of a common 11-gene ‘death from
cancer’ signature from both epithelial and nonepithelial
malignancies [23] may lend support to this hypothesis. The
implication of a germline polymorphism as opposed to a
somatic mutation for assessment of metastasis risk is that risk
assessment can be done using any tissue at the time of
diagnosis or even before diagnosis of a primary tumor [24].
The existence of inherited metastasis risk factors (or
prospective metastatic biomarkers) has potentially highly
significant implications for our models of metastasis, clinical
prognosis and the development of tailored treatment.
However, the specific genes and mechanisms responsible for
this heritable effect on metastasis remain to be fully identified,
and more evidence is required to establish their influence on
human disease.
Cost/benefits
Although the actual cost of performing gene expression
analysis is likely to be higher than those of determining
conventional clinical and histopathological markers, the
potential savings in terms of avoiding over-treatment, based
on existing guidelines, could be substantial.
Cost/benefit analyses of using a new 70-gene commercially
available assay as an alternative to clinical guidelines to
identify high-risk patients for adjuvant chemotherapy were
recently described [25]. The study found that the use of gene
expression profiling to guide treatment would result in a cost
saving of US$2882 per woman treated, but in a greater
number of women developing recurrent disease and a smaller
gain in quality-adjusted life years (QALYs), compared with
existing methods. As with any test that defines groups within
a population, a gene expression threshold must be chosen to
discriminate between high and low risk women. Adjustments
to the level at which this test threshold was set had a greater
effect on the number of QALYs obtained by gene expression
profiling than did adjustments of the estimates of chemo-
therapy-associated risks and benefits. The discrimination
threshold of the gene expression profile could not be
adjusted to a level that would detect high risk individuals
sensitively enough to match the performance of the
conventional guidelines in terms of QALYs gained. This study
highlights the extreme importance of setting the discrimina-
tion level correctly and concluded that further refinement and
testing are needed before routine clinical use of the 70-gene
assay can be recommended.
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The genes that make up a gene expression signature are by
their nature dependent on the patient and tumour
characteristics, array platform, normalization method and
statistical thresholds for gene selection or the classification
algorithm employed. Using a particular dataset to generate a
predictive profile has its own inherent bias based on its
attributes. By simply changing the members of ‘training’ and
‘test’ sets, Ein-Dor and coworkers [26] were able to identify
more than 1000 genes that are related to survival, even when
using the same dataset and methods as van’t Veer and
colleagues [7,8], and found that many different but equally
predictive lists of 70 genes could have been produced from
the same analysis. Rather than indicating that the data are
meaningless, this suggests that the predictive value is real
but highly context dependent.
The comparability of different microarray platforms is a major
issue. The lack of overlap (three genes) between the 70-gene
signature of the Amsterdam group (cDNA arrays) [7,8] and
the 76-gene signature of the Rotterdam group (Affymetrix
oligonucleotide arrays) [9] has been claimed as evidence that
genomic approaches are unreliable. A multiple random
validation strategy has been suggested to combat this
problem [27]. However, although validation is essential, a
predictive signature determined from a highly selected group
of samples cannot possibly be expected to replicate the exact
findings when applied to a different group of samples using a
different gene expression platform. The differences between
signatures in different studies are due to varying inclusion
criteria (age, lymph node status, diameter of tumour, adjuvant
treatment, among other factors), the platform (cDNA or
oligonucleotide arrays, or reverse transcription polymerase
chain reaction) and data analysis methods used in each
study.
Nevertheless, Sorlie and coworkers [6] recently showed that
even with different array platforms the breast cancer subtypes
are distinguishable at the unsupervised level. Despite some
variation in the most differentially expressed genes identified
by each array platform, there was a highly significant overlap
at the pathway level. This confirms that distinct molecular
mechanisms underlie the clinically relevant subtypes of breast
cancer, and that perturbations in these mechanisms can be
detected reliably by different platforms. Similarly, Hu and
colleagues [11] recently described and validated a refined
‘intrinsic’ classification signature that is conserved across
microarray platforms and also uncovered a possible ‘new’
subtype characterized by the high expression of interferon-
regulated genes.
Validation of new findings with independent data is essential
for us to believe that the results are indeed ‘real’, and this has
been encouraged and facilitated by making it a prerequisite
for publication that gene expression datasets are publicly
accessible according to the MIAME (Minimum Information
About a Microarray Experiment) guidelines [28], allowing
complete datasets to be downloaded. Public access has
permitted studies in which gene expression data from several
studies are re-analyzed. For example, meta-analyses of
multiple experiments using different platforms have resulted in
new predictive signatures that perform as well or better than
the platform specific signature [29,30] (Figure 1). These
approaches remove the inherent bias of a single microarray
platform and are able to concentrate on genes that are
consistently differentially expressed, regardless of the
technology used. However, they may be limited by the
number of common genes represented.
Improvements in technology and analysis
Advances in gene expression technology are continually
being made, with increasing numbers of more clearly defined
transcripts represented on each new generation of array.
Improvements in RNA extraction, quantification and quality
assessment (such as the RNA integrity number [31]) will
increase reliability of expression profiling. Improved labelling
and amplification protocols enable profiling to be performed
on smaller amounts of tissue.
Laser capture microdissection has been used to ensure that
RNA is isolated from tumour rather than normal tissue.
Alternatively, small amounts of RNA have been isolated from
formalin fixed, paraffin embedded blocks rather than fresh
frozen tissue, and can be used in assays such as the
multigene reverse transcription polymerase chain reaction
classifier commercially known as OncotypeDX [32,33].
These are important considerations because taking fresh
tissue for gene expression analysis from a tiny tumour can
compromise histopathology reporting. These improved
methods will be required to circumvent the logistical
difficulties, costs and time associated with collecting fresh
tissue straight from a tumour at the time of surgery.
Multicentre studies will be facilitated by techniques for
extraction of intact RNA from preserved tissues, because
these will obviate the need to collect and transport frozen
material.
Although much of the additional information from expression
profiling of primary tumours is consistent with that for existing
markers, there have been some conflicting results; for
example, some women found to be ERBB2 positive by
immunohistochemistry were classified in the luminal cluster
and not the ErbB2 group [4]. It may be difficult to choose the
most appropriate treatment when different assays conflict,
and of course existing technologies should not be
discounted. Fluorescent in situ hybridization is still
considered the most reliable and consistent method to
determine ERBB2 status [34].
Trials: what is required
Large trials are now needed to evaluate fully the use of
genomic signatures. Recruitment has begun for the
Breast Cancer Research    Vol 8 No 5 Sims et al.
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Chemotherapy) trial, which will be run under the auspices of
the TRANSBIG consortium and coordinated by the EORTC
(European Organisation for Research and Treatment of
Cancer). It will study women with node-negative disease who
are aged 18-75 years. One of its primary aims is to establish
whether women with a good prognosis gene expression
signature (assessed using Mammaprint, a commercially
available form of the 70-gene profile reported by van’t Veer
and coworkers [7,8]) but poor prognosis clinicopathological
status (as assessed using the Adjuvant! Online software [35])
can be spared chemotherapy without reducing metastasis-free
survival. One of the secondary objectives is to identify and
validate expression profiles that predict response to
chemotherapy and endocrine therapy. Another large trial
currently underway is being run by the US Intergroup PACCT
(Program for the Assessment of Clinical Cancer Tests) to
assess the OncotypeDX signature in 10,046 women aged 18-
75 years with operable, node negative, ER positive and/or
progesterone receptor positive breast cancer. In this study,
patients with an intermediate risk OncotypeDX score will be
randomized to combination chemotherapy and endocrine
therapy (the usual treatment) or endocrine therapy alone. These
two studies are seen as the best way to establish whether the
genomic signatures will lead to the desired goal of better
targeting treatment to those who will benefit and so yielding
improvements in breast cancer mortality and morbidity.
With individualization of therapy, it is inevitable that women in
a study will be undergoing many different treatment regimens.
Consequently, it may become more difficult to obtain
sufficiently high numbers of women with similar regimens to
compare with each other to evaluate new tests with adequate
statistical power. Many of the profiles have been developed in
well defined groups of women (Table 1), and clearly it is
important that validation takes place in equivalent groups of
women undergoing the same treatment, because prognostic
differences evident in one group may not be apparent in a
differently treated group. It is likely that new profiles will be
developed in the years ahead, and the need for large
numbers of patients will necessitate large multinational trials.
New drugs are rapidly being developed. In order for gene
expression profiling to be useful, the initiation of trials
evidently needs to keep pace with the introduction of new
treatments that are shown to be best practice.
Conclusion
Fundamentally, there is a major leap from the observation that
gene expression profiles can predict outcome to the use of
Available online http://breast-cancer-research.com/content/8/5/214
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Figure 1
Combining datasets. Combining data from multiple gene expression studies of human breast tumours reveals significant overlap, despite inherent
differences in the technology used. One example, shown here, is a 90-gene meta-signature reported by Shen and coworkers [30], which achieved
equal or better prognostic performance compared with the individual signatures derived from four studies of breast cancer recurrence using
different microarray platforms. Primary tumours were taken at diagnosis from patients who later had recurrent (R) or recurrence-free (RF) disease.
Individual heat maps show increased expression (red) and decreased expression (green) of the raw data from four separate experiments using
different platforms. With permission from Shen and coworkers [30].these profiles in treatment decisions. In recent years great
advances in our knowledge of the molecular biology of breast
tumours have been achieved using genomic approaches. It is
perhaps not surprising that genomic signatures tend to
outperform the pre-existing clinical models when one
considers the large numbers of additional factors that are
being taken into account, and that precision of measurement
of these factors is continuous (gene expression levels) rather
than categorical (for example, tumour grade and lymph node
status). Despite their promise, some caution is required with
the new approaches. A study comparing the power of gene
expression measurements with that of conventional
prognostic markers found that transcriptional profiling
approaches did not perform noticeably better than indices
constructed from the clinical variables [36].
The challenge that lies ahead is to convert the increased
information potentially available from gene expression
profiling of breast tumours into useful tools that can optimize
clinical decisions and tailor treatment regimens to an
individual patient, ultimately improving outcome and reducing
overall costs. This will take place through advances in sample
processing, microarray technology and statistical analysis
techniques to obtain consistency. Finally, investment in trials
of this genomic technology is needed now if savings in costs
of treatment, particularly with the rise in availability of
expensive drugs, are to be made in the long term.
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